Literature DB >> 32161106

Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies.

Brian H Santich1,2, Jeong A Park2, Hoa Tran2, Hong-Fen Guo2, Morgan Huse3, Nai-Kong V Cheung4.   

Abstract

T cell-bispecific antibodies (BsAbs) couple cytotoxic T lymphocytes to tumor cells, inducing their destruction. Although there are more than 60 classes of BsAbs in development, the relative importance of parameters such as interdomain spacing or spatial configuration is largely unknown. Here, we dissected a symmetric dual bivalent BsAb platform (IgG-[L]-scFv: antitumor IgG with anti-CD3 scFv fused to the light chains) to explore the importance of valency and spatial configuration for BsAb-induced T cell cytotoxicity. Our results revealed that placing tumor and T cell binding domains on the same side of a BsAb (cis-configuration) elicited substantially stronger antitumor activity, in vitro and in vivo, compared to positioning them on opposite sides (trans-configuration). Moreover, using two cis-modules in the same BsAb further improved cytotoxicity (up to 2000-fold). In addition, separating antigen-binding components with a single Ig domain (CL) markedly enhanced cytokine release and in vivo tumor responses compared to smaller (G4S1) or larger (CH1-CH2-CH3) spacers. These findings provide guidelines for improving BsAb function and highlight the importance of spatial configuration and dual bivalency as development parameters.
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32161106      PMCID: PMC7437947          DOI: 10.1126/scitranslmed.aax1315

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  35 in total

1.  A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens.

Authors:  Gregory L Moore; Cristina Bautista; Erik Pong; Duc-Hanh T Nguyen; Jonathan Jacinto; Araz Eivazi; Umesh S Muchhal; Sher Karki; Seung Y Chu; Greg A Lazar
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

Review 2.  Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety.

Authors:  Diego Ellerman
Journal:  Methods       Date:  2018-11-03       Impact factor: 3.608

3.  Blinatumomab (Blincyto): lessons learned from the bispecific t-cell engager (BiTE) in acute lymphocytic leukemia (ALL).

Authors:  G Friberg; D Reese
Journal:  Ann Oncol       Date:  2017-08-01       Impact factor: 32.976

Review 4.  T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.

Authors:  Z Wu; N V Cheung
Journal:  Pharmacol Ther       Date:  2017-08-20       Impact factor: 12.310

5.  Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.

Authors:  Hong Xu; Ming Cheng; Hongfen Guo; Yuedan Chen; Morgan Huse; Nai-Kong V Cheung
Journal:  Cancer Immunol Res       Date:  2014-12-26       Impact factor: 11.151

6.  Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody.

Authors:  Torsten Dreier; Grit Lorenczewski; Christian Brandl; Patrick Hoffmann; Uwe Syring; Frank Hanakam; Peter Kufer; Gert Riethmuller; Ralf Bargou; Patrick A Baeuerle
Journal:  Int J Cancer       Date:  2002-08-20       Impact factor: 7.396

7.  Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3.

Authors:  Dionysos Slaga; Diego Ellerman; T Noelle Lombana; Rajesh Vij; Ji Li; Maria Hristopoulos; Robyn Clark; Jennifer Johnston; Amy Shelton; Elaine Mai; Kapil Gadkar; Amy A Lo; James T Koerber; Klara Totpal; Rodney Prell; Genee Lee; Christoph Spiess; Teemu T Junttila
Journal:  Sci Transl Med       Date:  2018-10-17       Impact factor: 17.956

8.  Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody.

Authors:  Mahiuddin Ahmed; Ming Cheng; Irene Y Cheung; N K Cheung
Journal:  Oncoimmunology       Date:  2015-04-27       Impact factor: 8.110

9.  Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody.

Authors:  Andres Lopez-Albaitero; Hong Xu; Hongfen Guo; Linlin Wang; Zhihao Wu; Hoa Tran; Sarat Chandarlapaty; Maurizio Scaltriti; Yelena Janjigian; Elisa de Stanchina; Nai-Kong V Cheung
Journal:  Oncoimmunology       Date:  2017-03-10       Impact factor: 8.110

10.  Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies.

Authors:  Nathan D Trinklein; Duy Pham; Ute Schellenberger; Ben Buelow; Andrew Boudreau; Priya Choudhry; Starlynn C Clarke; Kevin Dang; Katherine E Harris; Suhasini Iyer; Brett Jorgensen; Payal P Pratap; Udaya S Rangaswamy; Harshad S Ugamraj; Omid Vafa; Arun P Wiita; Wim van Schooten; Roland Buelow; Shelley Force Aldred
Journal:  MAbs       Date:  2019-02-20       Impact factor: 5.857

View more
  19 in total

Review 1.  Immunotherapy of Pediatric Solid Tumors: Treatments at a Crossroads, with an Emphasis on Antibodies.

Authors:  Dana L Casey; Nai-Kong V Cheung
Journal:  Cancer Immunol Res       Date:  2020-02       Impact factor: 11.151

2.  Characterization of a novel bispecific antibody targeting tissue factor-positive tumors with T cell engagement.

Authors:  Zhidi Pan; Jie Chen; Xiaodong Xiao; Yueqing Xie; Hua Jiang; Baohong Zhang; Huili Lu; Yunsheng Yuan; Lei Han; Yuexian Zhou; Huifang Zong; Lei Wang; Rui Sun; Jianwei Zhu
Journal:  Acta Pharm Sin B       Date:  2021-11-03       Impact factor: 14.903

Review 3.  Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?

Authors:  David Kegyes; Catalin Constantinescu; Louise Vrancken; Leo Rasche; Celine Gregoire; Bogdan Tigu; Diana Gulei; Delia Dima; Alina Tanase; Hermann Einsele; Stefan Ciurea; Ciprian Tomuleasa; Jo Caers
Journal:  J Hematol Oncol       Date:  2022-06-07       Impact factor: 23.168

4.  T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia.

Authors:  Sayed Shahabuddin Hoseini; Mallika Vadlamudi; Madelyn Espinosa-Cotton; Hoa Tran; Yi Feng; Hong-Fen Guo; Hong Xu; Irene Cheung; Nai-Kong V Cheung
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

5.  Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release.

Authors:  Jeong A Park; Brian H Santich; Hong Xu; Lawrence G Lum; Nai-Kong V Cheung
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 12.469

6.  Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies.

Authors:  Sayed Shahabuddin Hoseini; Madelyn Espinosa-Cotton; Hong-Fen Guo; Nai-Kong V Cheung
Journal:  J Immunother Cancer       Date:  2020-11       Impact factor: 13.751

7.  One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics.

Authors:  Wei Chen; Fan Yang; Carole Wang; Jatin Narula; Edward Pascua; Irene Ni; Sheng Ding; Xiaodi Deng; Matthew Ling-Hon Chu; Amber Pham; Xiaoyue Jiang; Kevin C Lindquist; Patrick J Doonan; Tom Van Blarcom; Yik Andy Yeung; Javier Chaparro-Riggers
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

8.  A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy.

Authors:  Brian H Santich; Sarah M Cheal; Mahiuddin Ahmed; Michael R McDevitt; Ouathek Ouerfelli; Guangbin Yang; Darren R Veach; Edward K Fung; Mitesh Patel; Daniela Burnes Vargas; Aiza A Malik; Hong-Fen Guo; Pat B Zanzonico; Sebastien Monette; Adam O Michel; Charles M Rudin; Steven M Larson; Nai K Cheung
Journal:  Clin Cancer Res       Date:  2020-09-21       Impact factor: 13.801

Review 9.  Format and geometries matter: Structure-based design defines the functionality of bispecific antibodies.

Authors:  Steffen Dickopf; Guy J Georges; Ulrich Brinkmann
Journal:  Comput Struct Biotechnol J       Date:  2020-05-14       Impact factor: 7.271

10.  An optimal antitumor response by a novel CEA/CD3 bispecific antibody for colorectal cancers.

Authors:  Ninghai Wang; Harshal Patel; Irene C Schneider; Xin Kai; Avanish K Varshney; Li Zhou
Journal:  Antib Ther       Date:  2021-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.